BeOne Medicines Ltd. Announces Record Date for 2026 Annual General Meeting
BeOne Medicines Ltd. Announces Record Date for 2026 Annual General Meeting
BeOne Medicines Ltd. (Stock Code: 06160), a Switzerland-incorporated corporation listed on the Hong Kong Stock Exchange, has issued an important announcement for its shareholders concerning the upcoming 2026 Annual General Meeting (AGM).
Key Highlights of the Announcement
- Record Date Set: The company has declared that the record date for determining the right to attend and vote at the 2026 AGM will be at 12:00 p.m. Central European Summer Time (6:00 p.m. Hong Kong time) on Friday, May 22, 2026.
- Share Registration Deadline: To be eligible to participate and vote at the AGM, shareholders must ensure that all properly completed transfer forms, along with the relevant share certificates, are lodged with the company’s branch share registrar in Hong Kong—Computershare Hong Kong Investor Services Limited—no later than 4:30 p.m. Hong Kong time on Friday, May 22, 2026.
- AGM Details: The specific date, time, and venue of the AGM, as well as related proxy materials, will be available in the official notice of the AGM, which will be published on the Hong Kong Stock Exchange website (www.hkexnews.hk) on April 28, 2026.
Important Information for Shareholders
- Entitlement to Vote: Only shareholders who are registered by the stated deadline will be entitled to attend and vote at the AGM. This is a critical cut-off for those wishing to influence key decisions or resolutions at the meeting.
- Action Required: Shareholders holding physical share certificates should ensure all transfer documentation is completed and submitted on time to avoid missing out on their voting rights.
- Potential Share Price Impact: While this announcement is largely procedural, the AGM is typically an event where significant corporate decisions (such as director appointments, dividends, or strategic resolutions) may be discussed and voted on, which could impact share valuation. Investors should monitor the AGM notice and proxy materials for any price-sensitive items on the agenda.
Board Composition Update
As of the date of this announcement, the company’s Board of Directors is comprised of a diverse group of industry professionals:
- Mr. John V. Oyler (Chairman and Executive Director)
- Dr. Xiaodong Wang (Non-executive Director)
- Dr. Olivier Brandicourt (Independent Non-executive Director)
- Dr. Margaret Han Dugan (Independent Non-executive Director)
- Mr. Michael Goller (Independent Non-executive Director)
- Mr. Anthony C. Hooper (Independent Non-executive Director)
- Mr. Ranjeev Krishana (Independent Non-executive Director)
- Dr. Alessandro Riva (Independent Non-executive Director)
- Dr. Corazon (Corsee) D. Sanders (Independent Non-executive Director)
- Ms. Shalini Sharp (Independent Non-executive Director)
- Mr. Qingqing Yi (Independent Non-executive Director)
This broad mix of expertise could be relevant for investors, as changes to the board or new appointments may be announced at the AGM, potentially impacting company strategy and value.
Next Steps for Investors
- Monitor for AGM Notice: Investors should look out for the official notice of the AGM and accompanying proxy materials to be published on April 28, 2026. These documents will provide further details on the meeting’s agenda, any proposed resolutions, and items for shareholder approval.
- Prepare for Voting: Ensure that all shareholdings are properly registered by the stated deadlines to secure voting rights at the AGM.
Disclaimer: This article is for informational purposes only and does not constitute investment advice. Investors should consult the official company filings and consider their own investment objectives and risk tolerance before making any decisions. The details provided herein are based on the company’s public announcement as of April 28, 2026, and are subject to change.
View BEONE MEDICINES Historical chart here
